Supplementary Data 6 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation

Supplementary Data 6 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation

<p>Supplementary Data 6: Association between individual metabolites and radiation survival</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Priyanka Gopal (15050862) (author)
Autres auteurs:	Brian D. Yard (15050865) (author), Aaron Petty (15050868) (author), Jessica C. Lal (15050871) (author), Titas K. Bera (15050874) (author), Trung Q. Hoang (15050877) (author), Alexandru D. Buhimschi (15050880) (author), Mohamed E. Abazeed (14936313) (author)
Publié:	2025
Sujets:	Cancer Cancer Detection and Diagnosis Methods and Technology Biomarkers Genetic biomarkers Computational Methods Algorithms Gene Technologies Mutation detection methods Lung Cancer
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Supplementary Data 1 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
par: Priyanka Gopal (15050862)
Publié: (2025)

Supplementary Data 2 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
par: Priyanka Gopal (15050862)
Publié: (2025)

Supplementary Data 3 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
par: Priyanka Gopal (15050862)
Publié: (2025)

Supplementary Data 4 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
par: Priyanka Gopal (15050862)
Publié: (2025)

Supplementary Data 5 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
par: Priyanka Gopal (15050862)
Publié: (2025)

Supplementary Figure S6 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
par: Leon J. Wils (15055780)
Publié: (2025)

Supplementary Table S7 from Gene Fusion Detection and Characterization in Long-Read Cancer Transcriptome Sequencing Data with FusionSeeker
par: Yu Chen (14962271)
Publié: (2025)

Supplementary Figure S1 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
par: Leon J. Wils (15055780)
Publié: (2025)

Supplementary Figure S10 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
par: Leon J. Wils (15055780)
Publié: (2025)

Supplementary Figure S11 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
par: Leon J. Wils (15055780)
Publié: (2025)

Supplementary Figure S12 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
par: Leon J. Wils (15055780)
Publié: (2025)

Supplementary Figure S2 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
par: Leon J. Wils (15055780)
Publié: (2025)

Supplementary Figure S4 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
par: Leon J. Wils (15055780)
Publié: (2025)

Supplementary Figure S5 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
par: Leon J. Wils (15055780)
Publié: (2025)

Supplementary Figure S7 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
par: Leon J. Wils (15055780)
Publié: (2025)

Supplementary Figure S8 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
par: Leon J. Wils (15055780)
Publié: (2025)

Supplementary Figure S9 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
par: Leon J. Wils (15055780)
Publié: (2025)

Supplementary Table S1 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
par: Aleksandar Obradovic (7549517)
Publié: (2025)

Supplementary Table S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
par: Aleksandar Obradovic (7549517)
Publié: (2025)

Supplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
par: Joel R. Eisner (15132120)
Publié: (2025)

Supplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
par: Joel R. Eisner (15132120)
Publié: (2025)

Supplementary Table S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
par: Joel R. Eisner (15132120)
Publié: (2025)

Figure S1 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
par: Subhamoy Chakraborty (16648124)
Publié: (2025)

Figure S2 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
par: Subhamoy Chakraborty (16648124)
Publié: (2025)

Figure S3 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
par: Subhamoy Chakraborty (16648124)
Publié: (2025)

Supplementary Tables 1-3 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
par: Subhamoy Chakraborty (16648124)
Publié: (2025)

Figure 6 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
par: David Milewski (15050643)
Publié: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
par: Tobias Kessler (17079209)
Publié: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
par: Lavanya Sivapalan (15314248)
Publié: (2025)

Supplementary Tables S1-S10 from <i>ACTA2</i> Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer
par: Sunho Park (15053897)
Publié: (2025)

Figure 1 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
par: David Milewski (15050643)
Publié: (2025)

Figure 2 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
par: David Milewski (15050643)
Publié: (2025)

Figure 3 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
par: David Milewski (15050643)
Publié: (2025)

Figure 4 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
par: David Milewski (15050643)
Publié: (2025)

Figure 5 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
par: David Milewski (15050643)
Publié: (2025)

Supplementary Table S1-S3 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
par: David Milewski (15050643)
Publié: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
par: Tobias Kessler (17079209)
Publié: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
par: Tobias Kessler (17079209)
Publié: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
par: Tobias Kessler (17079209)
Publié: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
par: Tobias Kessler (17079209)
Publié: (2025)

Cannot write session to /tmp/vufind_sessions/sess_n4au7hbgrmjq0b19ru5ekg5a8f